RT Journal Article
SR Electronic
T1 Seasonal variation exists in B-Cell Precursor Childhood Acute Lymphoblastic Leukemia diagnosis, but not in Acute Myeloid Leukemia, Brain Tumors or Solid Tumors – a Swedish population-based study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.12.23285595
DO 10.1101/2023.02.12.23285595
A1 Bychkov, Gleb
A1 Bang, Benedicte
A1 Engsner, Niklas
A1 Heyman, Mats Marshall
A1 Nordenvall, Anna Skarin
A1 Tettamanti, Giorgio
A1 Herold, Nikolas
A1 Taylan, Fulya
A1 Pontén, Emeli
A1 Albert, Jan
A1 Jörnsten, Rebecka
A1 Strannegård, Claes
A1 Nordgren, Ann
YR 2024
UL http://medrxiv.org/content/early/2024/07/16/2023.02.12.23285595.abstract
AB Background B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common malignancy in children and adolescents. A combination of genetic predisposition, exposures to diverse microbiota, infections, and an immature immune system have been associated with BCP-ALL development. Genetic aberrations causing the progression of preleukemic cells to overt BCP-ALL have been identified, but drivers behind these aberrations remain largely unknown.Methods We analyzed seasonal variation in 1,380 BCP-ALLs, 385 acute myeloid leukemias (AML), 3,052 solid tumors and 1,945 brain tumors retrieved from the population-based Swedish Childhood Cancer Registry (SCCR), aged 0-18 years at diagnosis and diagnosed between 1995-2017. Cases were first aggregated into three types of quarters (3-month periods) based on the time of BCP-ALL diagnosis. Then, data was analyzed using a Bayesian Generalized Auto Regressive Integrated Moving Average with external variables (GARIMAX) model, adapted for count data via a negative binomial distribution.Results An informative seasonal variation in BCP-ALL with peak quarters in Jul-Sep and Jun-Aug was identified. Manual inspection revealed that the largest number of BCP-ALL cases (138 (10%)) was observed in August. No seasonal variation was detected in the comparison groups of childhood AML, brain tumors, or solid tumors.Conclusions Diagnosis of childhood BCP-ALL in Sweden displays seasonal variation with a peak during the summer months, in contrast to other tumor types. We present putative explanation models for this incidence peak that build on the hypothesis of infectious exposure/-s triggering the final progression to BCP-ALL diagnosis in at-risk individuals. Further studies using GARIMAX in larger populations with genetically confirmed BCP-ALL subtypes are warranted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the Swedish Childhood Cancer Fund the Swedish Cancer Society the Cancer Society of Stockholm the Swedish Research Council the Stockholm Regional Council Mary Beves Stiftelse for Barncancerforskning the Swedish Rare Diseases Research foundation Berth von Kantzows foundation Karolinska Institutet Research Foundation Hallsten Research foundation, Stiftelsen Frimurare Barnhuset in Stockholm and the Stockholm County CouncilAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Regional Ethical Review Board in Stockholm, Sweden (ethics permit numbers 2018/1849-32)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors